Monitor CTAD conference presentations for any qualitative insights on trial execution or patient experience, but the next material catalyst remains the topline ALTITUDE-AD data expected in late 2026.
Price Chart
Executive Summary
Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug at the CTAD conference in November 2026. The presentations cover baseline characteristics, patient/partner experience, and treatment expectations, but no new efficacy or safety data are disclosed. This is a routine scientific conference update with no material impact on the stock.
Key Facts
- Three poster presentations on Phase 2 ALTITUDE-AD trial of sabirnetug at CTAD conference (Nov 16-19, 2026)
- Presentations cover baseline characteristics, patient/partner experience, and treatment expectations/motivations
- No new efficacy or safety data disclosed in the press release
- Topline results from ALTITUDE-AD expected in late 2026
- Sabirnetug has Fast Track designation from FDA for early Alzheimer's disease
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech
Risk Factors
- No new efficacy or safety data disclosed — stock may be range-bound until topline results
- Phase 2 failure risk remains high for early-stage Alzheimer's programs
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386215 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-3 | $2.27 | awaiting T+20 | — | $2.27 (+0.01%) |
Oct 26, 2026 today | 8-K | $2.07 | awaiting T+20 | — | $2.27 (+9.71%) |
Oct 26, 2026 today | Press Release | $2.05 | awaiting T+20 | — | $2.27 (+10.73%) |
Oct 22, 2026 4d ago | Press Release | $2.06 | awaiting T+20 | — | $2.27 (+10.19%) |
Oct 19, 2026 7d ago | Press Release | $2.02 | awaiting T+20 | — | $2.27 (+12.66%) |
Sep 16, 2026 5w ago | 8-K | $2.61 $1.82 | ▼ −30.46% | ▼ −33.64% | $2.27 (−13.03%) |
Aug 12, 2026 10w ago | Institutional Cluster | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | 8-K | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | Press Release | $2.51 $2.86 | ▼ −13.94% | ▼ −15.84% | $2.27 (+9.56%) |
Jun 17, 2026 18w ago | Insider Cluster | $2.26 $2.17 | ▼ −3.98% | ▼ −4.52% | $2.27 (+0.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers